Hanall Biopharma (009420) — Cash Flow Reinvestment Rate
Hanall Biopharma (009420) has a Cash Flow Reinvestment Rate of 0.45x as of September 2025, reinvesting ₩3.27 Billion (capex ₩3.27 Billion ) from operating cash flow of ₩7.34 Billion. See how much free cash does Hanall Biopharma generate to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Hanall Biopharma Cash Flow Reinvestment Rate (2011–2024)
Historical reinvestment intensity for Hanall Biopharma across 10 annual periods. For the full cash flow conversion analysis, see Hanall Biopharma (009420) cash flow conversion.
Annual Cash Flow Reinvestment Rate for Hanall Biopharma (2011–2024)
Year-by-year capital reinvestment analysis for Hanall Biopharma. See Hanall Biopharma (009420) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.80x | ₩26.19 Billion | ₩9.36 Billion | ₩23.07 Billion | ▲ +293.4% |
| 2023 | 0.71x | ₩21.08 Billion | ₩29.64 Billion | ₩9.20 Billion | ▲ +211.1% |
| 2022 | 0.23x | ₩5.76 Billion | ₩25.20 Billion | ₩2.83 Billion | ▼ -99.1% |
| 2021 | 25.62x | ₩21.52 Billion | ₩839.87 Million | ₩4.61 Billion | ▲ +211.9% |
| 2020 | 8.21x | ₩7.63 Billion | ₩929.29 Million | ₩2.56 Billion | ▲ +452.7% |
| 2019 | 1.49x | ₩30.45 Billion | ₩20.49 Billion | ₩2.12 Billion | ▲ +533.8% |
| 2017 | 0.23x | ₩9.88 Billion | ₩42.14 Billion | ₩1.73 Billion | ▼ -93.8% |
| 2016 | 3.76x | ₩14.84 Billion | ₩3.95 Billion | ₩4.03 Billion | ▲ +277.6% |
| 2012 | 0.99x | ₩2.18 Billion | ₩2.20 Billion | ₩2.18 Billion | ▲ +1627.8% |
| 2011 | 0.06x | ₩426.70 Million | ₩7.41 Billion | ₩426.70 Million | — |